Physician profile
Bruce Brouillette
NPI 1194753913
$4,256.22
in general payments reported to CMS, 2019-2025
29 companies · $635 in 2025
The $635 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $785 · 2020: $323 · 2021: $425 · 2022: $706 · 2023: $621 · 2024: $762 · 2025: $635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,018.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,017.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $814.07 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $544.40 | 2019-2025 | Mounjaro, Zepbound |
| Abbott Laboratories | $421.71 | 2021-2025 | Freestyle Libre 3 |
| Amgen INC. | $399.46 | 2020-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $326.44 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $275.84 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $260.05 | 2019-2024 | Jardiance, Tradjenta |
| Novo Nordisk INC | $203.98 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $171.22 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $113.08 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $86.34 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $84.37 | 2021-2024 | |
| Dexcom, INC. | $78.35 | 2024 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $63.97 | 2023-2024 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $62.11 | 2021-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $57.27 | 2022-2025 | |
| Mylan Specialty L.P. | $54.96 | 2021-2024 | Yupelri |
| Shield Therapeutics INC | $30.11 | 2022-2024 | |
| Bausch Health US, LLC | $29.06 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $25.39 | 2023 | Epkinly |
| Phathom Pharmaceuticals, INC. | $22.97 | 2024 | Voquezna |
| Itamar Medical INC | $22.76 | 2025 | Watchpatone |
| Boston Scientific Corporation | $20.81 | 2019 | |
| Sumitomo Pharma America, INC. | $18.97 | 2025 | Gemtesa |
| Shire North American Group INC | $15.06 | 2019 | |
| Eisai INC. | $14.03 | 2021 | |
| Exact Sciences Corporation | $13.69 | 2024 | Cologuard Collection Kit |
| Arbor Pharmaceuticals, INC. | $12.90 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Brouillette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.